Shots:
- Cumberland reported topline data from P-II (FIGHT DMD) trial assessing ifetroban (150/300mg, QD) vs PBO in DMD pts (n=41) for 12mos.; funded via the US FDA orphan products grant
- Study showed that ifetroban (300mg) led to 3.3% overall LVEF improvement (1EP), with a 1.8% increase vs 1.5% decline; on comparison with matched natural history controls, it depicted 5.4% improvement vs 3.6% decline in LVEF. Data analysis & P-II meeting with the US FDA are underway
- Additionally, a study at Vanderbilt University Medical Center demonstrated ifetroban’s protective effects against cardiomyopathy in multiple preclinical models of muscular dystrophy; data was published in The JAHA
Ref: PR Newswire |Â Image: Cumberland Pharmaceuticals
Related News:- Cumberland Pharmaceuticals’ Ifetroban Secures the US FDA’s ODD and RPDD for Duchenne Muscular Dystrophy
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com